- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2025 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Featured Content
European Biotech Targeting Anti-ageing
Oct 2nd 2024
Novel mitophagy inducers and gene therapies that restore cellular function and decelerate the ageing process.
Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?
Mar 4th 2024
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Training for Operational Excellence
Dec 3rd 2023
The bio/pharmaceutical industry is struggling with the challenge of staffing and training.
Billions of Reasons to be Buoyant
Sep 2nd 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
Latest Videos
Latest News
Pfizer and Evotec Partner for Drug Discovery
July 12th 2024
Pfizer and Evotec will focus on early discovery research for therapeutics targeting metabolic and infectious diseases.
uniQure to Sell Its Commercial Gene Therapy Manufacturing Operations in Massachusetts to Genezen
July 10th 2024
The acquisition of uniQure’s Lexington, Mass., manufacturing operations will boost Genezen’s late-phase and commercial gene therapy development and manufacturing services.
Cell-Free Protein Synthesis Technology to be Made More Accessible Through LenioBio and Labscoop Partnership
July 4th 2024
LenioBio and Labscoop's new strategic partnership is aimed at increasing access to scalable cell-free protein synthesis technology across North America.
Aurigene to Provide Cell Therapy Discovery Services to Edity to Support Clinical Development
July 2nd 2024
This collaboration aims to support and accelerate clinical development of advanced and novel technologies.
AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition
June 29th 2024
This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.
Johnson & Johnson Completes Proteologix Acquisition, Gains Bispecific Antibody Assets
June 28th 2024
Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition.
Roche and Ascidian Therapeutics Collaborate on Treatments for Neurological Diseases
June 18th 2024
The research collaboration and licensing agreement will focus on the discovery and development of RNA exon editing therapeutics.
Pushing Boundaries to Revolutionize Chronic Inflammation Therapy
June 14th 2024
Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions.
Syntegon Acquires Telstar
June 11th 2024
Syntegon will expand its processing and packaging by acquiring the Spanish equipment supplier.
Sterling Invests in Expansion of Integrated ADC Services
May 31st 2024
Sterling is strengthening its development and manufacturing services for ADCs with a dedicated GMP suite at its Wisconsin facility.